Vanda Q3 2024 revenue up 23% to $47.7M; guidance raised; net loss $5.3M

Vanda Pharmaceuticals Inc.

2024-Q3 EPS reported -$0.24 revenue$145,587,000

Q3 total net product sales $47.7M (+23% YoY); Fanapt $23.9M (+12%), HETLIOZ $17.9M (+2%), PONVORY $5.9M (-32% QoQ).
Net loss $5.3M vs net income $0.1M in Q3 2023; diluted EPS loss $0.09.
Cash $376.3M; guidance raised: FY revenue $190-210M, year-end cash $370-390M.
Fanapt bipolar I launch: new patient starts +90% Q3 2024 vs Q3 2023; Fanapt LAI Phase III starts Q4 2024.
Milsaperidone NDA for schizophrenia/bipolar I expected early 2025; tradipitant NDA for motion sickness in Q4 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.